EUCTR2010-023457-11-BE进行中（未招募）1 期
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer - TIREG
Z Leuven0 个研究点目标入组 37 人开始时间: 2011年1月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •-Failure of two lines of cytotoxic chemotherapy (ovarian cancer) or one line of cytotoxic chemotherapy (endometrial cancer)
- •-ECOG Status 1-2
- •-No previous chemotherapy for 3 months
- •-Confirmed histological evidence of either ovarian or primary peritoneal malignancy or endometrial cancer. All histological types will be included.
- •-Assessable disease by imaging (either CT Scan or MRI scan) will need to be present or alternatively, if absent, CA 125 levels should be at least twice normal and shown to have been increased on two occasions at least one week apart.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Documented autoimmune disease
- •-Currently ongoing systemic corticosteroid therapy and/or immune suppressant therapy
- •-Venous access is predicted to obviate frequent blood samples
研究者
相似试验
尚未招募
2 期
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour responseRecurrent Ovarian CancerCancer - Ovarian and primary peritonealACTRN12608000013369Royal Women's Hospital37
进行中（未招募）
不适用
The influence of immunotherapy and chemotherapy accompanying endurance training on incidence and severity of cognitive deficits as well as other therapy-induced side effects and complications in oncological patients. A randomized controlled trialDIVERSEC00-C75Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissueDRKS00011390niversitäres Centrum für Tumorerkrankungen (UCT) FrankfurtKrankenhaus NordwestKlinik für Onkologie und Hämatologie2
已完成
不适用
Immunological aspects of combined chemotherapy and immunotherapy with HPV16 E6/E7 Synthetic Long Peptide vaccination in patients with advanced cervical cancer.cancer of the cervix10038594cervical cancerNL-OMON36470eids Universitair Medisch Centrum18
已完成
不适用
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant SettingEsophagus CancerNCT05615129Guangdong Provincial People's Hospital350
进行中（未招募）
1 期
Stereotactic Body Radiation in combination with immunotherapy-chemotherapy in patients with Metastatic Non-Small Cell Lung Cancer.Patients with both squamous and nonsquamous metastatic non-small cell lung cancer (NSCLC) wild type in EGFR, KRAS, ALK and ROS1.MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002453-28-ITAZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA132